美托洛尔联合曲美他嗪治疗老年冠心病伴心力衰竭的效果分析
2020-12-23张道全
张道全

【摘要】 目的 探討美托洛尔联合曲美他嗪治疗老年冠心病伴心力衰竭的临床效果。方法 80例老年冠心病伴心力衰竭患者, 依据用药方案不同分为对照组和观察组, 各40例。对照组患者采用美托洛尔治疗, 观察组采用美托洛尔联合曲美他嗪治疗。比较两组治疗效果, 治疗前后心功能指标、6 min步行实验(6MWT)、血清炎症因子指标。结果 观察组总有效率95.00%高于对照组的80.00%, 差异有统计学意义(P<0.05)。治疗后, 观察组左室射血分数(LVEF)、6MWT均高于对照组, 左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均低于对照组, 差异有统计学意义(P<0.05)。治疗后, 观察组超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、及白介素-6(IL-6)水平分别为(2.61±0.13)mg/L、(4.15±0.62)mg/L、(10.26±2.26)ng/L, 均低于对照组的(4.43±0.26)mg/L、(6.98±1.01)mg/L、(17.16±3.95)ng/L, 差异有统计学意义(P<0.05)。结论 老年冠心病伴心力衰竭患者采用美托洛尔联合曲美他嗪治疗, 可显著提升疗效, 并改善患者的心功能及机体炎性反应。
【关键词】 冠心病;心力衰竭;美托洛尔;曲美他嗪
DOI:10.14163/j.cnki.11-5547/r.2020.31.039
Effect analysis of combination of metoprolol and trimetazidine in the treatment of senile coronary heart failure ZHANG Dao-quan. Baotou Mongolian Medicine Hospital of Traditional Chinese Medicine, Baotou 014040, China
【Abstract】 Objective To discuss the clinical effect of combination of metoprolol and trimetazidine in the treatment of senile coronary heart failure. Methods A total of 80 senile patients with coronary heart disease and heart failure were divided into control group and observation group according to different regimens, with 40 cases in each group. The control group was treated with metoprolol, and the observation group was treated with metoprolol and trimetazidine. The therapeutic effect, cardiac function indexes, 6-min walking test (6MWT) and serum inflammatory factor indexes were compared between the two groups. Results The total effective rate 95.00% of the observation group was higher than 80.00% of the control group, and the difference was statistically significant (P<0.05). After treatment, the left ventricular ejection fraction (LVEF) and 6MWT of the two groups were higher than those of the control group, and left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) were lower than those of the control group, and the difference was statistically significant (P<0.05). After treatment, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) of the observation group were lower than (4.43±0.26) mg/L, (6.98±1.01) mg/L, (17.16±3.95) ng/L of the control group, and the difference was statistically significant (P<0.05). Conclusion The combination of metoprolol and trimetazidine can significantly improve the efficacy and cardiac function of elderly patients with coronary heart disease and heart failure, and is beneficial to improve the bodys inflammatory response.
【Key words】 Coronary heart disease; Heart failure; Metoprolol; Trimetazidine
冠心病的发生是基于患者冠状动脉病变、痉挛以及粥样硬化等基础上, 致使心肌供血障碍从而诱发的严重心血管疾病。冠心病在老年人群体中具有较高的发病率, 心力衰竭则是冠心病患者的常见严重性并发症, 此类患者心肌收缩能力进一步减弱, 同时血氧供应量无法满足正常机体代谢需求, 对于患者生命健康具有严重威胁[1]。目前对于冠心病心力衰竭患者主要采用药物方案治疗, 然而临床药物种类繁多, 疗效差異较大。为此本文将着重分析美托洛尔联合曲美他嗪治疗老年冠心病伴心力衰竭患者的临床效果, 报告如下。
1 资料与方法
1. 1 一般资料 抽取2018年10月~2019年9月本院收治的80例老年冠心病伴心力衰竭患者, 依据用药方案不同分为对照组和观察组, 各40例。观察组男23例, 女17例;年龄60~87岁, 平均年龄(72.6±10.3)岁;冠心病病程2~16年, 平均病程(7.2±4.2)年;纽约心脏病协会(NYHA)心功能分级:Ⅱ级患者11例, Ⅲ级患者14例, Ⅳ级患者15例。对照组男21例, 女19例;年龄60~86岁, 平均年龄(72.4±9.5)岁;冠心病病程2~15年, 平均病程(7.3±4.0)年;NYHA心功能分级:Ⅱ级患者10例, Ⅲ级患者16例, Ⅳ级患者14例。……
